ClinicalTrials.gg
CompletedNCT05640245Updated Sep 10, 2026Results posted

Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

A Phase 2 interventional study of Sonelokimab and Placebo in Arthritis, Psoriatic, sponsored by MoonLake Immunotherapeutics AG. Completed at 42 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by MoonLake Immunotherapeutics AG · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
207
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 92 studies in Arthritis, Psoriatic with a site in Poland — 6 open to participants now, 25 under way, 18 of them phase 3. Arthritis, Psoriatic · Poland.

Enrollment
66th of 90
207 · median 399
Started
2022
with 4 others
Phase 2
21 of 92
1 open now
Registered
74th of 92
by date

Among the 92 studies in Arthritis, Psoriatic with a site in Poland, this one is the 66th largest by enrollment of the 90 interventional ones that give a count, is one of 5 that started in 2022, is one of 21 in phase 2, and was the 74th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

6 of the 92 studies in Arthritis, Psoriatic with a site in Poland are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Arthritis, Psoriatic with a site in Poland, or all of them as a file.
02

Study summary

This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with active psoriatic arthritis. The study includes adalimumab treatment as an active reference arm.

Read the detailed description

Patients will be randomized to receive one of three sonelokimab treatment regimes, adalimumab or placebo. Primary efficacy evaluation will take place at Week 12. Patients will be allocated to a further 12 weeks of treatment with sonelokimab or adalimumab based on response assessment at week 12. In certain countries, treatment will end at week 12.

03

Conditions studied

  • Arthritis, Psoriatic

Keywords

  • Arthritis, Psoriatic
  • Skin Diseases
  • Joint Diseases
  • Arthritis
  • Psoriasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant is ≥18 years of age;
  2. Participant has a confirmed diagnosis of PsA per the 2006 Classification criteria for Psoriatic Arthritis (CASPAR) with symptoms for ≥6 months prior to the Screening Visit;
  3. Participant has active disease (defined by a TJC68 of ≥3 and a SJC66 of ≥3);
  4. Participant has either current active PsO or a dermatologist confirmed history of PsO;
  5. Participant tests negative for rheumatoid factor (RF) at the Screening Visit;
  6. Participant tests negative for anti-cyclic citrullinated peptide (CCP) antibodies at the Screening Visit;
  7. Participant must be, in the opinion of the investigator, a suitable candidate for treatment with adalimumab per approved local product information.

Exclusion criteria

Exclusion Criteria:

  1. Participant with known to sonelokimab or any of its ;
  2. Participant with known hypersensitivity to adalimumab or any of its excipients;
  3. Participant who has previously failed on anti-interleukin (IL)-17 therapy;
  4. Participant who has previously failed on anti-tumor necrosis factor alpha (TNFα) therapy;
  5. Participant who has had previous exposure to more than 2 biologic agents of any type to treat PsA prior to the Screening Visit;
  6. Participant who has a diagnosis of chronic inflammatory conditions other than PsO or PsA;
  7. Participant who has a diagnosis of arthritis mutilans
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
207 participants (actual)

Study arms

  • Experimental
    sonelokimab dose regimen 1

    Subjects randomized to this arm will receive assigned sonelokimab dosage regimen 1

    Drug: Sonelokimab

  • Experimental
    sonelokimab dose regimen 2

    Subjects randomized to this arm will receive assigned sonelokimab dosage regimen 2

    Drug: Sonelokimab

  • Experimental
    sonelokimab dose regimen 3

    Subjects randomized to this arm will receive assigned sonelokimab dosage regimen 3

    Drug: Sonelokimab

  • Placebo comparator
    Placebo

    Subjects randomized to this arm will receive placebo

    Drug: Placebo

  • Active comparator
    adalimumab

    Subjects randomized to this arm will receive adalimumab

    Drug: Adalimumab

Interventions

  • randomized treatment; parallel group

    Also known as: M1095

  • DrugPlacebo

    randomized treatment; parallel-group

  • randomized treatment; parallel-group

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving an American College of Rheumatology 50% (ACR50) Response at Week 12

    The ACR50 response criteria was a response of at least 50% improvement from baseline based on both swollen joint count (66 joints) and tender joint count (68 joints), and at least 50% improvement from baseline in at least 3 of the following 5 variables: 1) participant's assessment of arthritis pain (PtAAP) on a Visual Analog Scale (VAS, no pain =0 to severe pain =100); 2) participant's global assessment of disease activity (PtGADA) on a VAS (very well =0 to very poor =100); 3) physician's global assessment of disease activity (phGADA) on a VAS (very well =0 to very poor =100); 4) participant's assessment of physical function as measured by the Health Assessment Questionnaire Disability Index (HAQ-DI) (overall score ranging from 0 \[mild disability\] to 3 \[very severe disability\]); and 5) high sensitivity C-reactive protein (hs-CRP, decrease indicates improvement). A non-responder imputation (NRI) method was used for missing data.

    Time frame: At Week 12

Secondary outcomes

  1. Percentage of Participants Achieving an American College of Rheumatology 20% (ACR20) Response at Weeks 2, 4, and 8 and 12

    The ACR20 response criteria was a response of at least 20% improvement from baseline based on both swollen joint count (66 joints) and tender joint count (68 joints), and at least 20% improvement from baseline in at least 3 of the following 5 variables: 1) PtAAP on a VAS (no pain =0 to severe pain =100); 2) PtGADA on a VAS (very well =0 to very poor =100); 3) phGADA on a VAS (very well =0 to very poor =100); 4) participant's assessment of physical function as measured by the HAQ-DI (overall score ranging from 0 \[mild disability\] to 3 \[very severe disability\]); and 5) hs-CRP (decrease indicates improvement). An NRI method was used for missing data. ACR20 response rate at Week 12 was analyzed as a key secondary outcome measure.

    Time frame: At Weeks 2, 4, 8, and 12

  2. Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 4, 8 and 12, in Participants With Psoriasis Involving at Least 3% Body Surface Area (BSA) at Baseline

    The PASI is a validated tool to dynamically assess psoriasis severity. The PASI produces a numeric score that ranges from 0 (no disease) to 72 (maximal disease). A PASI90 response was defined as greater than or equal to 90% improvement (reduction) in PASI score from baseline. An NRI method was used for missing data. PASI90 response at Week 12 was analyzed as a key secondary outcome measure.

    Time frame: At Weeks 4, 8, and 12

  3. Percentage of Participants Achieving an ACR50 Response at Weeks 2, 4, and 8

    The ACR50 response criteria was a response of at least 50% improvement from baseline based on both swollen joint count (66 joints) and tender joint count (68 joints), and at least 50% improvement from baseline in at least 3 of the following 5 variables: 1) PtAAP on a VAS (no pain =0 to severe pain =100); 2) PtGADA on a VAS (very well =0 to very poor =100); 3) phGADA on a VAS (very well =0 to very poor =100); 4) participant's assessment of physical function as measured by the HAQ-DI (overall score ranging from 0 \[mild disability\] to 3 \[very severe disability\]); and 5) hs-CRP (decrease indicates improvement). An NRI method was used for missing data.

    Time frame: At Weeks 2, 4, and 8

  4. Percentage of Participants Achieving an American College of Rheumatology 70% (ACR70) Response at Weeks 2, 4, 8, and 12

    The ACR70 response criteria was a response of at least 70% improvement from baseline based on both swollen joint count (66 joints) and tender joint count (68 joints), and at least 70% improvement from baseline in at least 3 of the following 5 variables: 1) PtAAP on a VAS (no pain =0 to severe pain =100); 2) PtGADA on a VAS (very well =0 to very poor =100); 3) phGADA on a VAS (very well =0 to very poor =100); 4) participant's assessment of physical function as measured by the HAQ-DI (overall score ranging from 0 \[mild disability\] to 3 \[very severe disability\]); and 5) hs-CRP (decrease indicates improvement). An NRI method was used for missing data.

    Time frame: At Weeks 2, 4, 8, and 12

  5. Percentage of Participants Achieving Minimal Disease Activity at Week 12

    Minimal disease activity was defined as meeting 5 of the following 7 criteria: tender joint count (68 joints) ≤1; swollen joint count (66 joints) ≤1; psoriasis area and severity index ≤1 or psoriasis affecting ≤1% of body surface area; PtAAP ≤15 on a VAS (0 = no pain to 100 = severe pain); PtGADA ≤20 on a VAS (0 = very well to 100 = very poor); HAQ-DI ≤0.5 (overall score ranging from 0 \[mild disability\] to 3 \[very severe disability\]); and Leeds Enthesitis Index (LEI) ≤1 (overall score ranging from 0 to 6, with higher scores indicating greater disease severity). An NRI method was used for missing data.

    Time frame: At Week 12

  6. Percentage of Participants Who Achieved a PASI75 Response at Week 12, in Participants With Psoriasis Involving at Least 3% BSA at Baseline

    The PASI is a validated tool to dynamically assess psoriasis severity. The PASI produces a numeric score that ranges from 0 (no disease) to 72 (maximal disease). A PASI75 response was defined as greater than or 75% improvement (reduction) in PASI score from baseline. An NRI method was used for missing data.

    Time frame: At Week 12

  7. Percentage of Participants Achieving a PASI100 Response at Week 12, in Participants With Psoriasis Involving at Least 3% BSA at Baseline

    The PASI is a validated tool to dynamically assess psoriasis severity. The PASI produces a numeric score that ranges from 0 (no disease) to 72 (maximal disease). A PASI100 response was defined as 100% improvement (reduction) in PASI score from baseline. An NRI method was used for missing data.

    Time frame: At Week 12

  8. Change From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) Score at Week 12

    The mNAPSI is a tool to assess psoriatic nail involvement. Three groups of features (pitting, onycholysis, and oil-drop dyshromia and crumbling) for each fingernail are graded on a scale from 0 to 3. Four features (leukonychia, splinter hemorrhages, hyperkeratosis, and red spots in the lunula) are graded as either present (1) or absent (0) in each fingernail. The total score was calculated by summing the score for each feature and each fingernail and ranged from 0 to 130, with higher scores indicating greater nail disease. A negative change from baseline indicated an improvement in nail disease.

    Time frame: Baseline and Week 12

07

Results

Posted Sep 10, 2026

Participant flow

Participants were enrolled in 8 countries in the United States (US) and European Union (EU). The trial included a screening period of up to 4 weeks, a 12-week placebo-controlled treatment period (Part A), a 12-week active treatment period (Part B), and safety follow-up period of 8 weeks (± 7 days) after last dose of trial treatment (or 12 weeks \[± 7 days\] for participants enrolled in Czech Republic). In the US, only Part A was conducted, whereas in the EU, Parts A and B were conducted.

Part A
Participant flow — Part A
MilestonePart A: PlaceboPart A: Sonelokimab 60 mg Without InductionPart A: Sonelokimab 60 mg With InductionPart A: Sonelokimab 120 mg With InductionPart A: Adalimumab 40 mg Q2WPart B: Placebo to Sonelokimab 120 mg Q4WPart B: Sonelokimab 60 mg Without Induction to Sonelokimab 60 mg Q4WPart B: Sonelokimab 60 mg Without Induction to Sonelokimab 120 mg Q4WPart B: Sonelokimab 60 mg With Induction to Sonelokimab 60 mg Q4WPart B: Sonelokimab 60 mg With Induction to Sonelokimab 120 mg Q4WPart B: Sonelokimab 120 mg With Induction to Sonelokimab 120 mg Q4WPart B: Sonelokimab 120 mg With Induction to Adalimumab 40 mg Q2WPart B: Adalimumab 40 mg Q2W to Adalimumab 40 mg Q2WPart B: Adalimumab 40 mg Q2W to Sonelokimab 120 mg Q2W
Started4041414342000000000
Received treatment in part a3941414342000000000
Completed3741414241000000000
Not completed30011000000000
Withdrew: Withdrawal by subject10011000000000
Withdrew: Lack of efficacy10000000000000
Withdrew: Did not receive treatment10000000000000
Part B
Participant flow — Part B
MilestonePart A: PlaceboPart A: Sonelokimab 60 mg Without InductionPart A: Sonelokimab 60 mg With InductionPart A: Sonelokimab 120 mg With InductionPart A: Adalimumab 40 mg Q2WPart B: Placebo to Sonelokimab 120 mg Q4WPart B: Sonelokimab 60 mg Without Induction to Sonelokimab 60 mg Q4WPart B: Sonelokimab 60 mg Without Induction to Sonelokimab 120 mg Q4WPart B: Sonelokimab 60 mg With Induction to Sonelokimab 60 mg Q4WPart B: Sonelokimab 60 mg With Induction to Sonelokimab 120 mg Q4WPart B: Sonelokimab 120 mg With Induction to Sonelokimab 120 mg Q4WPart B: Sonelokimab 120 mg With Induction to Adalimumab 40 mg Q2WPart B: Adalimumab 40 mg Q2W to Adalimumab 40 mg Q2WPart B: Adalimumab 40 mg Q2W to Sonelokimab 120 mg Q2W
Started0000037345345365347
Completed0000035344345364325
Not completed00000201000122
Withdrew: Adverse event00000200000001
Withdrew: Withdrawal by subject00000001000111
Withdrew: Protocol violation00000000000010

Outcome measures

PrimaryPercentage of Participants Achieving an American College of Rheumatology 50% (ACR50) Response at Week 12

The ACR50 response criteria was a response of at least 50% improvement from baseline based on both swollen joint count (66 joints) and tender joint count (68 joints), and at least 50% improvement from baseline in at least 3 of the following 5 variables: 1) participant's assessment of arthritis pain (PtAAP) on a Visual Analog Scale (VAS, no pain =0 to severe pain =100); 2) participant's global assessment of disease activity (PtGADA) on a VAS (very well =0 to very poor =100); 3) physician's global assessment of disease activity (phGADA) on a VAS (very well =0 to very poor =100); 4) participant's assessment of physical function as measured by the Health Assessment Questionnaire Disability Index (HAQ-DI) (overall score ranging from 0 \[mild disability\] to 3 \[very severe disability\]); and 5) high sensitivity C-reactive protein (hs-CRP, decrease indicates improvement). A non-responder imputation (NRI) method was used for missing data.

Time frame:
At Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving an American College of Rheumatology 50% (ACR50) Response at Week 12
Percentage of participantsPart A: PlaceboPart A: Sonelokimab 60 mg Without InductionPart A: Sonelokimab 60 mg With InductionPart A: Sonelokimab 120 mg With InductionPart A: Adalimumab 40 mg Q2W
Percentage of Participants Achieving an American College of Rheumatology 50% (ACR50) Response at Week 1220.036.646.346.542.9
Statistical analysis
  • Part A: Placebo vs Part A: Sonelokimab 60 mg Without Induction · Regression, Logistic · p = 0.086 · Odds ratio (or): 2.430 · 95% CI 0.882 to 6.695Model included fixed effects for treatment and the stratification factors sex and prior biologic agent exposure.
  • Part A: Placebo vs Part A: Sonelokimab 60 mg With Induction · Regression, Logistic · p = 0.012 · Odds ratio (or): 3.612 · 95% CI 1.320 to 9.884Model included fixed effects for treatment and the stratification factors sex and prior biologic agent exposure.
  • Part A: Placebo vs Part A: Sonelokimab 120 mg With Induction · Regression, Logistic · p = 0.009 · Odds ratio (or): 3.992 · 95% CI 1.416 to 11.250Model included fixed effects for treatment and the stratification factors sex and prior biologic agent exposure.
SecondaryPercentage of Participants Achieving an American College of Rheumatology 20% (ACR20) Response at Weeks 2, 4, and 8 and 12

The ACR20 response criteria was a response of at least 20% improvement from baseline based on both swollen joint count (66 joints) and tender joint count (68 joints), and at least 20% improvement from baseline in at least 3 of the following 5 variables: 1) PtAAP on a VAS (no pain =0 to severe pain =100); 2) PtGADA on a VAS (very well =0 to very poor =100); 3) phGADA on a VAS (very well =0 to very poor =100); 4) participant's assessment of physical function as measured by the HAQ-DI (overall score ranging from 0 \[mild disability\] to 3 \[very severe disability\]); and 5) hs-CRP (decrease indicates improvement). An NRI method was used for missing data. ACR20 response rate at Week 12 was analyzed as a key secondary outcome measure.

Time frame:
At Weeks 2, 4, 8, and 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving an American College of Rheumatology 20% (ACR20) Response at Weeks 2, 4, and 8 and 12
Percentage of participantsPart A: PlaceboPart A: Sonelokimab 60 mg Without InductionPart A: Sonelokimab 60 mg With InductionPart A: Sonelokimab 120 mg With InductionPart A: Adalimumab 40 mg Q2W
Week 212.524.426.825.619.0
Week 430.048.851.248.854.8
Week 840.063.465.967.471.4
Week 1237.575.678.072.171.4
Statistical analysis
  • Part A: Placebo vs Part A: Sonelokimab 60 mg Without Induction · Regression, Logistic · p = <0.001 (Nominal p-value) · Odds ratio (or): 6.067 · 95% CI 2.194 to 16.779Model included fixed effects for treatment and the stratification factors sex and prior biologic agent exposure.
  • Part A: Placebo vs Part A: Sonelokimab 60 mg With Induction · Regression, Logistic · p = <0.001 · Odds ratio (or): 6.531 · 95% CI 2.360 to 18.073Model included fixed effects for treatment and the stratification factors sex and prior biologic agent exposure.
  • Part A: Placebo vs Part A: Sonelokimab 120 mg With Induction · Regression, Logistic · p = 0.002 · Odds ratio (or): 4.695 · 95% CI 1.807 to 12.200Model included fixed effects for treatment and the stratification factors sex and prior biologic agent exposure.
SecondaryPercentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 4, 8 and 12, in Participants With Psoriasis Involving at Least 3% Body Surface Area (BSA) at Baseline

The PASI is a validated tool to dynamically assess psoriasis severity. The PASI produces a numeric score that ranges from 0 (no disease) to 72 (maximal disease). A PASI90 response was defined as greater than or equal to 90% improvement (reduction) in PASI score from baseline. An NRI method was used for missing data. PASI90 response at Week 12 was analyzed as a key secondary outcome measure.

Time frame:
At Weeks 4, 8, and 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 4, 8 and 12, in Participants With Psoriasis Involving at Least 3% Body Surface Area (BSA) at Baseline
Percentage of participantsPart A: PlaceboPart A: Sonelokimab 60 mg Without InductionPart A: Sonelokimab 60 mg With InductionPart A: Sonelokimab 120 mg With InductionPart A: Adalimumab 40 mg Q2W
Week 47.79.450.033.312.5
Week 87.753.169.233.331.3
Week 1215.450.076.959.350.0
Statistical analysis
  • Part A: Placebo vs Part A: Sonelokimab 60 mg Without Induction · Regression, Logistic · p = 0.009 (Nominal p-value) · Odds ratio (or): 5.691 · 95% CI 1.558 to 20.791Model included fixed effects for treatment and stratification factors sex and prior biologic agent exposure; baseline score was included as covariate.
  • Part A: Placebo vs Part A: Sonelokimab 60 mg With Induction · Regression, Logistic · p = <0.001 · Odds ratio (or): 25.780 · 95% CI 5.411 to 122.835Model included fixed effects for treatment and stratification factors sex and prior biologic agent exposure; baseline score was included as covariate.
  • Part A: Placebo vs Part A: Sonelokimab 120 mg With Induction · Regression, Logistic · p = 0.003 · Odds ratio (or): 8.315 · 95% CI 2.077 to 33.282Model included fixed effects for treatment and stratification factors sex and prior biologic agent exposure; baseline score was included as covariate.
SecondaryPercentage of Participants Achieving an ACR50 Response at Weeks 2, 4, and 8

The ACR50 response criteria was a response of at least 50% improvement from baseline based on both swollen joint count (66 joints) and tender joint count (68 joints), and at least 50% improvement from baseline in at least 3 of the following 5 variables: 1) PtAAP on a VAS (no pain =0 to severe pain =100); 2) PtGADA on a VAS (very well =0 to very poor =100); 3) phGADA on a VAS (very well =0 to very poor =100); 4) participant's assessment of physical function as measured by the HAQ-DI (overall score ranging from 0 \[mild disability\] to 3 \[very severe disability\]); and 5) hs-CRP (decrease indicates improvement). An NRI method was used for missing data.

Time frame:
At Weeks 2, 4, and 8
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving an ACR50 Response at Weeks 2, 4, and 8
Percentage of participantsPart A: PlaceboPart A: Sonelokimab 60 mg Without InductionPart A: Sonelokimab 60 mg With InductionPart A: Sonelokimab 120 mg With InductionPart A: Adalimumab 40 mg Q2W
Week 25.04.97.39.32.4
Week 410.014.617.120.928.6
Week 810.022.026.823.335.7
SecondaryPercentage of Participants Achieving an American College of Rheumatology 70% (ACR70) Response at Weeks 2, 4, 8, and 12

The ACR70 response criteria was a response of at least 70% improvement from baseline based on both swollen joint count (66 joints) and tender joint count (68 joints), and at least 70% improvement from baseline in at least 3 of the following 5 variables: 1) PtAAP on a VAS (no pain =0 to severe pain =100); 2) PtGADA on a VAS (very well =0 to very poor =100); 3) phGADA on a VAS (very well =0 to very poor =100); 4) participant's assessment of physical function as measured by the HAQ-DI (overall score ranging from 0 \[mild disability\] to 3 \[very severe disability\]); and 5) hs-CRP (decrease indicates improvement). An NRI method was used for missing data.

Time frame:
At Weeks 2, 4, 8, and 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving an American College of Rheumatology 70% (ACR70) Response at Weeks 2, 4, 8, and 12
Percentage of participantsPart A: PlaceboPart A: Sonelokimab 60 mg Without InductionPart A: Sonelokimab 60 mg With InductionPart A: Sonelokimab 120 mg With InductionPart A: Adalimumab 40 mg Q2W
Week 202.44.94.70
Week 42.52.44.97.04.8
Week 82.512.212.216.316.7
Week 1212.524.429.325.628.6
SecondaryPercentage of Participants Achieving Minimal Disease Activity at Week 12

Minimal disease activity was defined as meeting 5 of the following 7 criteria: tender joint count (68 joints) ≤1; swollen joint count (66 joints) ≤1; psoriasis area and severity index ≤1 or psoriasis affecting ≤1% of body surface area; PtAAP ≤15 on a VAS (0 = no pain to 100 = severe pain); PtGADA ≤20 on a VAS (0 = very well to 100 = very poor); HAQ-DI ≤0.5 (overall score ranging from 0 \[mild disability\] to 3 \[very severe disability\]); and Leeds Enthesitis Index (LEI) ≤1 (overall score ranging from 0 to 6, with higher scores indicating greater disease severity). An NRI method was used for missing data.

Time frame:
At Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Minimal Disease Activity at Week 12
Percentage of participantsPart A: PlaceboPart A: Sonelokimab 60 mg Without InductionPart A: Sonelokimab 60 mg With InductionPart A: Sonelokimab 120 mg With InductionPart A: Adalimumab 40 mg Q2W
Percentage of Participants Achieving Minimal Disease Activity at Week 1220.026.843.937.235.7
SecondaryPercentage of Participants Who Achieved a PASI75 Response at Week 12, in Participants With Psoriasis Involving at Least 3% BSA at Baseline

The PASI is a validated tool to dynamically assess psoriasis severity. The PASI produces a numeric score that ranges from 0 (no disease) to 72 (maximal disease). A PASI75 response was defined as greater than or 75% improvement (reduction) in PASI score from baseline. An NRI method was used for missing data.

Time frame:
At Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved a PASI75 Response at Week 12, in Participants With Psoriasis Involving at Least 3% BSA at Baseline
Percentage of participantsPart A: PlaceboPart A: Sonelokimab 60 mg Without InductionPart A: Sonelokimab 60 mg With InductionPart A: Sonelokimab 120 mg With InductionPart A: Adalimumab 40 mg Q2W
Percentage of Participants Who Achieved a PASI75 Response at Week 12, in Participants With Psoriasis Involving at Least 3% BSA at Baseline26.971.984.666.765.6
SecondaryPercentage of Participants Achieving a PASI100 Response at Week 12, in Participants With Psoriasis Involving at Least 3% BSA at Baseline

The PASI is a validated tool to dynamically assess psoriasis severity. The PASI produces a numeric score that ranges from 0 (no disease) to 72 (maximal disease). A PASI100 response was defined as 100% improvement (reduction) in PASI score from baseline. An NRI method was used for missing data.

Time frame:
At Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a PASI100 Response at Week 12, in Participants With Psoriasis Involving at Least 3% BSA at Baseline
Percentage of participantsPart A: PlaceboPart A: Sonelokimab 60 mg Without InductionPart A: Sonelokimab 60 mg With InductionPart A: Sonelokimab 120 mg With InductionPart A: Adalimumab 40 mg Q2W
Percentage of Participants Achieving a PASI100 Response at Week 12, in Participants With Psoriasis Involving at Least 3% BSA at Baseline15.437.557.748.143.8
SecondaryChange From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) Score at Week 12

The mNAPSI is a tool to assess psoriatic nail involvement. Three groups of features (pitting, onycholysis, and oil-drop dyshromia and crumbling) for each fingernail are graded on a scale from 0 to 3. Four features (leukonychia, splinter hemorrhages, hyperkeratosis, and red spots in the lunula) are graded as either present (1) or absent (0) in each fingernail. The total score was calculated by summing the score for each feature and each fingernail and ranged from 0 to 130, with higher scores indicating greater nail disease. A negative change from baseline indicated an improvement in nail disease.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) Score at Week 12
Score on a scalePart A: PlaceboPart A: Sonelokimab 60 mg Without InductionPart A: Sonelokimab 60 mg With InductionPart A: Sonelokimab 120 mg With InductionPart A: Adalimumab 40 mg Q2W
Change From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) Score at Week 12-4.21 ± 1.33-9.68 ± 1.28-9.50 ± 1.34-10.15 ± 1.54-9.15 ± 1.19

Adverse events

Collected over Part A adverse event (AE) reporting: from first dose in Part A until end of Part A (EU participants continuing to Part B), or end of safety follow-up (US participants and EU participants not continuing to Part B); up to maximum of 23 weeks. Parts A+B AE reporting: from first dose until end of safety follow-up; up to maximum of 35 weeks. All-cause mortality: from enrollment until end of safety follow-up; up to maximum of 27 weeks in Part A or 39 weeks in Part B.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Placebo0/39 (0%)0/39 (0%)6/39 (15.4%)
Part A: Sonelokimab 60 mg Without Induction0/41 (0%)0/41 (0%)3/41 (7.3%)
Part A: Sonelokimab 60 mg With Induction0/41 (0%)1/41 (2.4%)5/41 (12.2%)
Part A: Sonelokimab 120 mg With Induction0/43 (0%)0/43 (0%)4/43 (9.3%)
Part A: Adalimumab 40 mg Q2W0/42 (0%)0/42 (0%)6/42 (14.3%)
Parts A+B: Total Sonelokimab 60 mg0/82 (0%)1/82 (1.2%)12/82 (14.6%)
Parts A+B: Total Sonelokimab 120 mg0/97 (0%)4/97 (4.1%)13/97 (13.4%)
Parts A+B: Total Adalimumab0/47 (0%)0/47 (0%)7/47 (14.9%)
Most frequent serious events
Most frequent serious events
EventPart A: PlaceboPart A: Sonelokimab 60 mg Without InductionPart A: Sonelokimab 60 mg With InductionPart A: Sonelokimab 120 mg With InductionPart A: Adalimumab 40 mg Q2WParts A+B: Total Sonelokimab 60 mgParts A+B: Total Sonelokimab 120 mgParts A+B: Total Adalimumab
AppendicitisInfections and infestations0/390/411/410/430/421/820/970/47
Pharyngeal abscessInfections and infestations0/390/410/410/430/420/821/970/47
Invasive breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/390/410/410/430/420/821/970/47
Radicular painNervous system disorders0/390/410/410/430/420/821/970/47
ArthritisMusculoskeletal and connective tissue disorders0/390/410/410/430/420/821/970/47
Subcutaneous emphysemaSkin and subcutaneous tissue disorders0/390/410/410/430/420/821/970/47
Most frequent other events
Most frequent other events
EventPart A: PlaceboPart A: Sonelokimab 60 mg Without InductionPart A: Sonelokimab 60 mg With InductionPart A: Sonelokimab 120 mg With InductionPart A: Adalimumab 40 mg Q2WParts A+B: Total Sonelokimab 60 mgParts A+B: Total Sonelokimab 120 mgParts A+B: Total Adalimumab
NasopharyngitisInfections and infestations1/390/411/410/433/425/825/974/47
Upper respiratory tract infectionInfections and infestations1/393/412/411/431/425/824/972/47
Injection site erythemaGeneral disorders0/390/412/413/431/423/823/971/47
PruritusSkin and subcutaneous tissue disorders2/390/410/410/430/420/820/970/47
Aspartate aminotransferase increasedInvestigations2/390/410/410/431/420/821/971/47

Baseline characteristics

The Full Analysis Set (FAS) included all randomized participants.

Age, Continuous
Age, Continuous(years)Part A: PlaceboPart A: Sonelokimab 60 mg Without InductionPart A: Sonelokimab 60 mg With InductionPart A: Sonelokimab 120 mg With InductionPart A: Adalimumab 40 mg Q2WTotal
Mean47.0 ± 14.3050.3 ± 13.8747.5 ± 12.6750.2 ± 10.3047.9 ± 12.3648.6 ± 12.70
Sex: Female, Male
Sex: Female, Male(Participants)Part A: PlaceboPart A: Sonelokimab 60 mg Without InductionPart A: Sonelokimab 60 mg With InductionPart A: Sonelokimab 120 mg With InductionPart A: Adalimumab 40 mg Q2WTotal
Female1921202121102
Male2120212221105
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: PlaceboPart A: Sonelokimab 60 mg Without InductionPart A: Sonelokimab 60 mg With InductionPart A: Sonelokimab 120 mg With InductionPart A: Adalimumab 40 mg Q2WTotal
Hispanic or Latino110103
Not Hispanic or Latino3940414242204
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: PlaceboPart A: Sonelokimab 60 mg Without InductionPart A: Sonelokimab 60 mg With InductionPart A: Sonelokimab 120 mg With InductionPart A: Adalimumab 40 mg Q2WTotal
White3940414341204
Not reported110013
08

Study locations

42 sites
  • Clinical Site
    Rancho Mirage, California 92260, United States
  • Clinical Site
    Duncansville, Pennsylvania 16635, United States
  • Clinical Site
    Pleven, 5800, Bulgaria
  • Clinical Site
    Pleven, 5803, Bulgaria
  • Clinical Site
    Plovdiv, 4002, Bulgaria
  • Clinical Site
    Plovdiv, 4003, Bulgaria
  • Clinical Site
    Rousse, 7002, Bulgaria
  • Clinical Site
    Sofia, 1336, Bulgaria
  • Clinical Site
    Stara Zagora, 6000, Bulgaria
  • Clinical Site
    Varna, 9000, Bulgaria
  • Clinical Site
    Ostrava, 702 00, Czechia
  • Clinical Site
    Tallinn, 10128, Estonia
  • Clinical Site
    Tartu, 20708, Estonia
  • Clinical Site
    Hamburg, 20095, Germany
  • Clinical Site
    Herne, 44649, Germany
  • Clinical Site
    Budapest, 1023, Hungary
  • Clinical Site
    Budapest, 1027, Hungary
  • Clinical Site
    Budapest, 1036, Hungary
  • Clinical Site
    Szentes, 6600, Hungary
  • Clinical Site
    Székesfehérvár, 8000, Hungary
  • Clinical Site
    Veszprém, 8200, Hungary
  • Clinical Site
    Bialystok, 15-077, Poland
  • Clinical Site
    Bialystok, 15-351, Poland
  • Clinical Site
    Bialystok, 15-879, Poland
  • Clinical Site
    Bydgoszcz, 85-065, Poland
  • Clinical Site
    Bydgoszcz, 85-168, Poland
  • Clinical Site
    Elblag, 82-300, Poland
  • Clinical Site
    Gdynia, 81-338, Poland
  • Clinical Site
    Krakow, 30-727, Poland
  • Clinical Site
    Lodz, 90-242, Poland
  • Clinical Site
    Nadarzyn, 05-830, Poland
  • Clinical Site
    Nowa Sól, 67-100, Poland
  • Clinical Site
    Olsztyn, 10-117, Poland
  • Clinical Site
    Poznan, 61-113, Poland
  • Clinical Site
    Sochaczew, 96-500, Poland
  • Clinical Site
    Swidnica, 58-100, Poland
  • Clinical Site
    Warsaw, 02-665, Poland
  • Clinical SIte
    Wroclaw, 52-416, Poland
  • Clinical Site
    Madrid, 28100, Spain
  • Clinical Site
    Sabadell, 8208, Spain
  • Clinical Site
    Santiago de Compostela, 15702, Spain
  • Clinical Site
    Seville, 41010, Spain
09

References and documents

Publications

  • McInnes IB, Coates LC, Mease PJ, Ogdie A, Kavanaugh A, Eder L, Schett G, Kivitz A, McGonagle D, Brennan N, Godwood A, Cullen E, Reich K, Ritchlin CT, Merola JF. Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial. Nat Med. 2025 Dec;31(12):4160-4171. doi: 10.1038/s41591-025-03971-6. Epub 2025 Oct 6. PubMed 41053449 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Sep 2023, 8 months.

Results were first posted in Sep 2026, 3 years after primary completion. A results delay was requested in Sep 2024.

Of 34 phase 2 interventional studies under Arthritis, Psoriatic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2022
First posted
Dec 7, 2022
StartActual
Dec 13, 2022
Primary completionActual
Sep 5, 2023
CompletionActual
Jan 15, 2024
Results delay requested
Sep 2, 2024
Results first posted
Sep 10, 2026
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05640245
Lead sponsor
MoonLake Immunotherapeutics AG
Responsible party
Sponsor
First posted
Dec 7, 2022
Start date
Dec 13, 2022
Primary completion
Sep 5, 2023
Completion
Jan 15, 2024
Results posted
Sep 10, 2026
Last update
Sep 10, 2026

Study contacts

MD
study director · MoonLake Immunotherapeutics AG

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonelokimab

Start the discussion